Curi Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-500
Closed -$37K – 711
2022
Q2
$37K Sell
500
-87,753
-99% -$6.59M 0.01% 252
2022
Q1
$7.93M Sell
88,253
-11,397
-11% -$1.05M 1.37% 30
2021
Q4
$11.2M Buy
+99,650
New +$12M 1.93% 23

Other funds holding XBI

Curi Wealth Management's XBI Position: Q3 2022 in Review

Curi Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 500 shares — an estimated $37K sold.

Curi Wealth Management first reported a position in XBI in Q4 2021 and held it in 3 quarters. The position peaked at $11.2M in Q4 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

  • Curi Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
  • Curi Wealth Management sold 500 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $37K.
  • Curi Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 3 quarters.
  • Curi Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $11.2M in Q4 2021.
  • 703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Curi Wealth Management's 13F filing for Q3 2022, filed 8 Nov 2022.